Wroclaw

• A Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacod … Recruiting
  2024-517957-29-00 4 2025-04-02 Mild Cognitive Impairment (MCI)
• A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t … Recruiting
  2024-512496-12-00 5 2025-04-01 Moderate to Severe Plaque Psoriasis
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici … Recruiting
  2024-516219-25-00 5 2025-03-25 psoriatic arthritis
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• A Phase 3 Efficacy and Safety Study of Pitolisant in Patients with Prader-Willi Syndrome Recruiting
  2023-508307-21-00 5 2025-03-19 Prader-Willi syndrome
• A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting
  2024-515566-13-00 5 2025-03-19 Diffuse Large B-Cell Lymphoma (DLBCL)
• A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant cell arteritis (EFFECTA) Recruiting
  2023-506623-29-01 4 2025-03-12 Giant cell arteritis
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept Recruiting
  2024-516380-81-00 4 2025-02-28 Treatment of IgAN
• A clinical study of tulisokibart in people with Crohn’s disease or ulcerative colitis (MK-7240-011) Recruiting
  2024-513533-20-00 5 2025-02-25 Crohn’s Disease or Ulcerative Colitis
• Clinical trial of molnupiravir (MK-4482) in adults who have COVID-19 and are not hospitalized, who are at high risk for serious illness from … Recruiting
  2023-507227-36-00 5 2025-02-21 SARS-CoV-2 (COVID-19) infection
• A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-514281-39-00 5 2025-02-14 Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
• A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-515008-38-00 5 2025-02-14 Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
• A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum Recruiting
  2024-514306-31-00 5 2025-02-13 Pyoderma gangrenosum
• C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant … Recruiting
  2024-511652-40-00 5 2025-02-05 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• A multicenter, randomized, blinded, placebo controlled, phase II study to evaluate the safety and efficacy of cell therapy based with artifi … Recruiting
  2023-505226-33-00 4 2025-01-28 Presymptomatic diabetes type 1 (stage 1)
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and pla … Recruiting
  2023-510338-10-00 5 2025-01-15 Recurrent herpes labialis (RHL)
• Treatment of acute ischemic stroke due to occlusion of a large vessel by mechanical thrombectomy in patients with unknown onset or not meeti … Recruiting
  2024-515062-13-00 5 2025-01-14 acute ischemic stroke caused by occlusion of a large vessel
• ZELA trial: Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developi … Recruiting
  2024-513420-41-00 10 2025-01-09 prematurity in neonates
• Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo … Recruiting
  2023-507560-39-00 5 2025-01-07 Acquired Antithrombin Deficiency (Heparin Resistance)
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 5 2024-12-20 Relapsed/refractory multiple myeloma in patients who have received 1 t
• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy
• A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared … Recruiting
  2023-504022-19-01 5 2024-12-13 Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)

Showing 265–288 of 838 trials